ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BigHat Biosciences, Inc.
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Shanghai Zhongshan Hospital
UNC Lineberger Comprehensive Cancer Center
Catholic University of the Sacred Heart
Recurv Pharma Inc
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bristol-Myers Squibb
ImmunityBio, Inc.
Universidad Europea de Madrid
University of Miami
University of Vermont
Sun Yat-sen University
Huazhong University of Science and Technology
Gustave Roussy, Cancer Campus, Grand Paris
Centre Antoine Lacassagne
Case Comprehensive Cancer Center
Casa di Cura Dott. Pederzoli
IRCCS San Raffaele
Zhejiang University
Klinik Hirslanden, Zurich
First Affiliated Hospital of Wenzhou Medical University
University of Rochester
University of Rochester
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Unity Health Toronto
M.D. Anderson Cancer Center
Swansea Bay University Health Board
Hospital Universitari de Bellvitge
HealthPartners Institute
Second Life Therapeutics
Second Affiliated Hospital, School of Medicine, Zhejiang University
IMGT Co., Ltd.
Fudan University
Hospices Civils de Lyon
Genfleet Therapeutics (Shanghai) Inc.
Alpha Tau Medical LTD.
Chifeng Tumor Hospital
Jinling Hospital, China
GE Healthcare
Shanghai Zhongshan Hospital
University of Nottingham
Institut Bergonié
West China Hospital
Rigshospitalet, Denmark
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shandong Cancer Hospital and Institute